A new study published in the Journal of Translational Medicine reports a rational engineering strategy designed to break that tolerance. Researchers led by a Danish team spanning the University of Copenhagen and the biotechnology company HERVolution Therapeutics systematically mutated the envelope protein of HERV-K, focusing on a short stretch known as the immunosuppressive domain, or ISD. This domain, conserved among retroviral envelope proteins, is thought to dampen innate immune signaling and help the virus evade detection. The team hypothesized that disabling this domain without destroying the overall structure of the envelope protein could convert a poorly immunogenic self-antigen into a potent vaccine immunogen capable of awakening T cells against HERV-K-expressing tumors.

The engineering effort centered on a single amino acid substitution. Through a mutational screen across the ISD region, the researchers identified a mutation designated Q525A, in which the glutamine at position 525 of the envelope protein is replaced with alanine. This variant, termed ISDmut, had a measurable effect on innate immune signaling: cells expressing the mutated envelope showed enhanced activation of nuclear factor kappa B, or NF-κB, a central transcription factor in inflammatory and antiviral responses. Importantly, the mutation did not sabotage the assembly of virus-like particles, meaning the engineered envelope still formed the particulate structures that present antigen to the immune system in a native-like configuration. Preserving this architecture while removing immunosuppressive function was the key design goal.

To probe how the engineered antigen behaves in human immune cells, the team transduced monocyte-derived dendritic cells, the professional antigen-presenting cells that orchestrate T cell responses, with HERV-K-ISDmut constructs. Using flow cytometry, RNA sequencing, and transmission electron microscopy, they found that the mutated envelope increased antigen expression and shifted dendritic cell gene expression toward pathways associated with antigen presentation and cell death, both of which favor productive immune priming. The dendritic cells carrying the engineered antigen were then co-cultured with peripheral blood mononuclear cells from healthy human donors. The result was robust expansion of both CD4-positive and CD8-positive T cells, and critically, the expanded T cells recognized HLA-matched tumor cells that naturally express HERV-K. This demonstrated that the human T cell repertoire, despite lifelong exposure to HERV-K as a self-antigen, retains usable anti-HERV-K reactivity that can be mobilized with the right immunogen.

The next question was whether the engineered antigen could induce immune responses in living organisms, where tolerance mechanisms operate at full strength. The researchers evaluated two delivery platforms: adenoviral vectors and lipid nanoparticle-formulated messenger RNA. In mice, both mRNA and adenoviral vectors encoding HERV-K-ISDmut elicited strong cellular and humoral immune responses. More demanding still, the team tested the construct in HERV-K transgenic mice, animals engineered to carry the human HERV-K gene and therefore immunologically tolerant to it, a model that closely mimics the situation in human patients. Vaccination broke this tolerance, inducing responses against an antigen the immune system had been trained to ignore. The platform was also evaluated in cynomolgus macaques, non-human primates whose immune systems are more similar to our own, where the vaccine induced antibody responses, providing early evidence of translational feasibility across species.

Immunogenicity alone does not guarantee therapeutic benefit, so the team moved to a tumor model. They used a murine metastatic renal carcinoma model in which the tumor cells were made to express the HERV-K envelope, recreating the antigen profile of HERV-K-positive human cancers. In this setting, immunization with an adenovirus-vectored HERV-K-ISDmut vaccine conferred increased survival compared with controls. The researchers also examined how the vaccine interacted with checkpoint blockade, the class of drugs that releases the brakes on T cells. Combining the vaccine with anti-PD-1 antibody therapy provided additional benefit, suggesting that a therapeutic cancer vaccine targeting HERV-K could be rationally paired with existing immunotherapies rather than competing with them.

The biological logic underlying this strategy deserves attention. HERV-K expression in tumors is not a random curiosity. Hypomethylation of the genome, a hallmark of transformed cells, reactivates endogenous retroviral loci that are silenced in healthy tissues. This creates what immunologists call a tumor-associated antigen with viral characteristics: it is foreign in sequence, yet encoded by the patient’s own DNA and expressed almost exclusively in malignant tissue. Unlike personalized neoantigen vaccines, which require sequencing and manufacturing tailored to each patient’s tumor mutations, a shared antigen such as HERV-K could in principle support an off-the-shelf vaccine applicable to broad patient populations across multiple cancer types. The study’s authors argue that this breadth is precisely what makes the engineered ISDmut antigen a promising platform rather than a single-disease tool.

The work also illustrates a broader principle in retrovirology and vaccine design: the immunosuppressive domains of retroviral envelopes are not merely viral evasion tools but engineering handles. Related ISD sequences exist in other retroviruses, including murine leukemia virus, and their immunomodulatory function has been mapped to specific residues that interfere with innate immune pathways. By mutating a single residue in the HERV-K ISD, the Danish team effectively converted a stealth signal into an adjuvant-like trigger, enhancing NF-κB activation and downstream antigen presentation while leaving the global fold of the envelope intact. This kind of structure-guided rational design, in which immune evasion features are deliberately removed from an antigen, may be applicable to other endogenous retroviral targets and to viral vector platforms where envelope-mediated immunosuppression limits efficacy.

Significant hurdles remain before this approach reaches patients. The tumor models used were transplant models with engineered HERV-K expression, and spontaneous tumors with heterogeneous antigen expression may behave differently. Safety is a central consideration: any therapy that breaks immune tolerance to a self-encoded antigen must demonstrate that it does not attack healthy tissues that express low levels of HERV-K, such as germline cells and certain embryonic tissues, and the primate study represents only an early step in that assessment. The preclinical work was funded by HERVolution Therapeutics, and several authors hold patents and equity related to the technology, so independent replication will be important. Nevertheless, the study provides a complete proof of concept, from molecular engineering through dendritic cell biology, T cell priming in human cells, tolerance breaking in transgenic animals, and survival benefit in a tumor model. The authors propose that HERV-K-ISDmut antigens should now be explored in future clinical trials, where the central question will be whether an ancient viral fossil, deliberately reawakened and stripped of its immunosuppressive armor, can be turned into a broadly applicable weapon against cancer.

Subject of Research: Engineering the HERV-K envelope immunosuppressive domain as a cancer vaccine immunogen

Article Title: Engineering human endogenous retrovirus-K for improving immunogenicity and broad cancer targeting

Article References: Müller, M. D., Neukirch, L., Ragonnaud, E., Bermejo, A. V., Daradoumis, J., Jaded, V., Engdal, E. S., Faas, F., Perez-Penco, M., Picon-Jara, C., Nielsen, K. N., Duvnjak, L., Boilesen, D. R., Kusiński, S., Skandorff, I., Skeltved, N., Trinh, L. L. N., Turner, L., Grunddal, K. V., … Holst, P. J. (2026). Engineering human endogenous retrovirus-K for improving immunogenicity and broad cancer targeting. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09012-1

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09012-1

Keywords: HERV-K, human endogenous retrovirus, cancer immunotherapy, therapeutic vaccine, immunosuppressive domain, dendritic cells, T cell response, adenoviral vector, mRNA vaccine, anti-PD-1, tumor-associated antigen, NF-kB signaling